Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Table of Contents

Highlights

  • Highlights
    Highlights of This Issue
    Mol Cancer Ther February 1 2018 17 (2) 329-329;

MCT Focus: Developmental Therapeutics in Radiation Oncology

  • MCT Focus: Developmental Therapeutics in Radiation Oncology
    Refining Radiation for the Next Century
    John S. Lazo
    Mol Cancer Ther February 1 2018 17 (2) 332-335; DOI:10.1158/1535-7163.MCT-17-1244

  • MCT Focus: Developmental Therapeutics in Radiation Oncology
    Lack of Constitutively Active DNA Repair Sensitizes Glioblastomas to Akt Inhibition and Induces Synthetic Lethality with Radiation Treatment in a p53-Dependent Manner
    Kamalakannan Palanichamy, Disha Patel, John R. Jacob, Kevin T. Litzenberg, Nicolaus Gordon, Kirstin Acus, Shin-ei Noda and Arnab Chakravarti
    Mol Cancer Ther February 1 2018 17 (2) 336-346; DOI:10.1158/1535-7163.MCT-17-0429

  • MCT Focus: Developmental Therapeutics in Radiation Oncology
    Identification of MEK162 as a Radiosensitizer for the Treatment of Glioblastoma
    Ravi S. Narayan, Ana Gasol, Paul L.G. Slangen, Fleur M.G. Cornelissen, Tonny Lagerweij, Hou Y.Y.E. Veldman, Rogier Dik, Jaap van den Berg, Ben J. Slotman, Tom Würdinger, Daphne A. Haas-Kogan, Lukas J.A. Stalpers, Brigitta G. Baumert, Bart A. Westerman, Jan Theys and Peter Sminia
    Mol Cancer Ther February 1 2018 17 (2) 347-354; DOI:10.1158/1535-7163.MCT-17-0480

  • MCT Focus: Developmental Therapeutics in Radiation Oncology
    Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example
    Iris Eke, Adeola Y. Makinde, Molykutty J. Aryankalayil, Veit Sandfort, Sanjeewani T. Palayoor, Barbara H. Rath, Lance Liotta, Mariaelena Pierobon, Emanuel F. Petricoin, Matthew F. Brown, Jayne M. Stommel, Mansoor M. Ahmed and C. Norman Coleman
    Mol Cancer Ther February 1 2018 17 (2) 355-367; DOI:10.1158/1535-7163.MCT-17-0262

  • MCT Focus: Developmental Therapeutics in Radiation Oncology | AuthorChoice
    The Neddylation Inhibitor Pevonedistat (MLN4924) Suppresses and Radiosensitizes Head and Neck Squamous Carcinoma Cells and Tumors
    Vanessa Vanderdys, Amir Allak, Fadila Guessous, Mouadh Benamar, Paul W. Read, Mark J. Jameson and Tarek Abbas
    Mol Cancer Ther February 1 2018 17 (2) 368-380; DOI:10.1158/1535-7163.MCT-17-0083

  • MCT Focus: Developmental Therapeutics in Radiation Oncology
    Radiosensitization In Vivo by Histone Deacetylase Inhibition with No Increase in Early Normal Tissue Radiation Toxicity
    Blaz Groselj, Jia-Ling Ruan, Helen Scott, Jessica Gorrill, Judith Nicholson, Jacqueline Kelly, Selvakumar Anbalagan, James Thompson, Michael R.L. Stratford, Sarah J. Jevons, Ester M. Hammond, Cheryl L. Scudamore, Martin Kerr and Anne E. Kiltie
    Mol Cancer Ther February 1 2018 17 (2) 381-392; DOI:10.1158/1535-7163.MCT-17-0011

  • MCT Focus: Developmental Therapeutics in Radiation Oncology
    Arginine Deprivation Therapy: Putative Strategy to Eradicate Glioblastoma Cells by Radiosensitization
    C. Noreen Hinrichs, Mirjam Ingargiola, Theresa Käubler, Steffen Löck, Achim Temme, Alvaro Köhn-Luque, Andreas Deutsch, Olena Vovk, Oleh Stasyk and Leoni A. Kunz-Schughart
    Mol Cancer Ther February 1 2018 17 (2) 393-406; DOI:10.1158/1535-7163.MCT-16-0807

  • MCT Focus: Developmental Therapeutics in Radiation Oncology
    HMG-CoA Reductase Inhibition Delays DNA Repair and Promotes Senescence After Tumor Irradiation
    Elena V. Efimova, Natalia Ricco, Edwardine Labay, Helena J. Mauceri, Amy C. Flor, Aishwarya Ramamurthy, Harold G. Sutton, Ralph R. Weichselbaum and Stephen J. Kron
    Mol Cancer Ther February 1 2018 17 (2) 407-418; DOI:10.1158/1535-7163.MCT-17-0288

  • MCT Focus: Developmental Therapeutics in Radiation Oncology
    A CRISPR/Cas9–Based Screening for Non-Homologous End Joining Inhibitors Reveals Ouabain and Penfluridol as Radiosensitizers
    Jie Du, Jun Shang, Fei Chen, Yushuo Zhang, Narui Yin, Ting Xie, Haowen Zhang, Jiahua Yu and Fenju Liu
    Mol Cancer Ther February 1 2018 17 (2) 419-431; DOI:10.1158/1535-7163.MCT-17-0090

  • MCT Focus: Developmental Therapeutics in Radiation Oncology
    A Chemical Modulator of p53 Transactivation that Acts as a Radioprotective Agonist
    Akinori Morita, Ippei Takahashi, Megumi Sasatani, Shin Aoki, Bing Wang, Shinya Ariyasu, Kaoru Tanaka, Tetsuji Yamaguchi, Akiko Sawa, Yurie Nishi, Tatsuro Teraoka, Shohei Ujita, Yosuke Kawate, Chihiro Yanagawa, Keiji Tanimoto, Atsushi Enomoto, Mitsuru Nenoi, Kenji Kamiya, Yasushi Nagata, Yoshio Hosoi and Toshiya Inaba
    Mol Cancer Ther February 1 2018 17 (2) 432-442; DOI:10.1158/1535-7163.MCT-16-0554

Small Molecule Therapeutics

  • Small Molecule Therapeutics | AuthorChoice
    A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma
    Shumei Song, Min Xie, Ailing W. Scott, Jiankang Jin, Lang Ma, Xiaochuan Dong, Heath D. Skinner, Randy L. Johnson, Sheng Ding and Jaffer A. Ajani
    Mol Cancer Ther February 1 2018 17 (2) 443-454; DOI:10.1158/1535-7163.MCT-17-0560

  • Small Molecule Therapeutics
    Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
    Kristen M. Smith, Patrick C. Fagan, Elena Pomari, Giuseppe Germano, Chiara Frasson, Colin Walsh, Ian Silverman, Paolo Bonvini and Gang Li
    Mol Cancer Ther February 1 2018 17 (2) 455-463; DOI:10.1158/1535-7163.MCT-17-0419

  • Small Molecule Therapeutics
    Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer
    Yan Huang, Wei Hu, Jie Huang, Fangrong Shen, Yunjie Sun, Cristina Ivan, Sunila Pradeep, Robert Dood, Monika Haemmerle, Dahai Jiang, Lingegowda S. Mangala, Kyunghee Noh, Jean M. Hansen, Heather J. Dalton, Rebecca A. Previs, Archana S. Nagaraja, Michael McGuire, Nicholas B. Jennings, Russell Broaddus, Robert L. Coleman and Anil K. Sood
    Mol Cancer Ther February 1 2018 17 (2) 464-473; DOI:10.1158/1535-7163.MCT-17-0006

  • Small Molecule Therapeutics
    COX-2/sEH Dual Inhibitor PTUPB Potentiates the Antitumor Efficacy of Cisplatin
    Fuli Wang, Hongyong Zhang, Ai-Hong Ma, Weimin Yu, Maike Zimmermann, Jun Yang, Sung Hee Hwang, Daniel Zhu, Tzu-yin Lin, Michael Malfatti, Kenneth W. Turteltaub, Paul T. Henderson, Susan Airhart, Bruce D. Hammock, Jianlin Yuan, Ralph W. de Vere White and Chong-Xian Pan
    Mol Cancer Ther February 1 2018 17 (2) 474-483; DOI:10.1158/1535-7163.MCT-16-0818

  • Small Molecule Therapeutics
    Inhibition of O-GlcNAcase Sensitizes Apoptosis and Reverses Bortezomib Resistance in Mantle Cell Lymphoma through Modification of Truncated Bid
    Sudjit Luanpitpong, Nawin Chanthra, Montira Janan, Jirarat Poohadsuan, Parinya Samart, Yaowalak U-Pratya, Yon Rojanasakul and Surapol Issaragrisil
    Mol Cancer Ther February 1 2018 17 (2) 484-496; DOI:10.1158/1535-7163.MCT-17-0390

  • Small Molecule Therapeutics
    Inhibition of MDM2 by a Rhein-Derived Compound AQ-101 Suppresses Cancer Development in SCID Mice
    Lubing Gu, Hailong Zhang, Tao Liu, Alexander Draganov, Sha Yi, Binghe Wang and Muxiang Zhou
    Mol Cancer Ther February 1 2018 17 (2) 497-507; DOI:10.1158/1535-7163.MCT-17-0566

  • Small Molecule Therapeutics
    Mechanism-informed Repurposing of Minocycline Overcomes Resistance to Topoisomerase Inhibition for Peritoneal Carcinomatosis
    Huang-Chiao Huang, Joyce Liu, Yan Baglo, Imran Rizvi, Sriram Anbil, Michael Pigula and Tayyaba Hasan
    Mol Cancer Ther February 1 2018 17 (2) 508-520; DOI:10.1158/1535-7163.MCT-17-0568

Cancer Biology and Translational Studies

  • Cancer Biology and Translational Studies
    Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance
    Atrish Bagchi, Jaafar N. Haidar, Scott W. Eastman, Michal Vieth, Michael Topper, Michelle D. Iacolina, Jason M. Walker, Amelie Forest, Yang Shen, Ruslan D. Novosiadly and Kathryn M. Ferguson
    Mol Cancer Ther February 1 2018 17 (2) 521-531; DOI:10.1158/1535-7163.MCT-17-0575

  • Cancer Biology and Translational Studies
    A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination
    Agnès Figueras, Elisenda Alsina-Sanchís, Álvaro Lahiguera, Manuel Abreu, Laura Muinelo-Romay, Gema Moreno-Bueno, Oriol Casanovas, Mariona Graupera, Xavier Matias-Guiu, August Vidal, Alberto Villanueva and Francesc Viñals
    Mol Cancer Ther February 1 2018 17 (2) 532-543; DOI:10.1158/1535-7163.MCT-17-0643

Large Molecule Therapeutics

  • Large Molecule Therapeutics | AuthorChoice
    β-Catenin mRNA Silencing and MEK Inhibition Display Synergistic Efficacy in Preclinical Tumor Models
    Shanthi Ganesh, Xue Shui, Kevin P. Craig, Martin L. Koser, Girish R. Chopda, Wendy A. Cyr, Chengjung Lai, Henryk Dudek, Weimin Wang, Bob D. Brown and Marc T. Abrams
    Mol Cancer Ther February 1 2018 17 (2) 544-553; DOI:10.1158/1535-7163.MCT-17-0605

  • Large Molecule Therapeutics | AuthorChoice
    Characterization of SGN-CD123A, A Potent CD123-Directed Antibody–Drug Conjugate for Acute Myeloid Leukemia
    Fu Li, May Kung Sutherland, Changpu Yu, Roland B. Walter, Lori Westendorf, John Valliere-Douglass, Lucy Pan, Ashley Cronkite, Django Sussman, Kerry Klussman, Michelle Ulrich, Martha E. Anderson, Ivan J. Stone, Weiping Zeng, Mechthild Jonas, Timothy S. Lewis, Maitrayee Goswami, Sa A. Wang, Peter D. Senter, Che-Leung Law, Eric J. Feldman and Dennis R. Benjamin
    Mol Cancer Ther February 1 2018 17 (2) 554-564; DOI:10.1158/1535-7163.MCT-17-0742

  • Large Molecule Therapeutics
    An Infrared Dye–Conjugated Virus-like Particle for the Treatment of Primary Uveal Melanoma
    Rhonda C. Kines, Isabella Varsavsky, Sanghamitra Choudhary, Debaditya Bhattacharya, Sean Spring, Roger McLaughlin, Shin J. Kang, Hans E. Grossniklaus, Demetrios Vavvas, Stephen Monks, John R. MacDougall, Elisabet de los Pinos and John T. Schiller
    Mol Cancer Ther February 1 2018 17 (2) 565-574; DOI:10.1158/1535-7163.MCT-17-0953

Models and Technologies

  • Models and Technologies | AuthorChoice
    The Novel Oncolytic Adenoviral Mutant Ad5-3Δ-A20T Retargeted to αvβ6 Integrins Efficiently Eliminates Pancreatic Cancer Cells
    Y. K. Stella Man, James A. Davies, Lynda Coughlan, Constantia Pantelidou, Alfonso Blázquez-Moreno, John F. Marshall, Alan L. Parker and Gunnel Halldén
    Mol Cancer Ther February 1 2018 17 (2) 575-587; DOI:10.1158/1535-7163.MCT-17-0671

Back to top
PreviousNext
Molecular Cancer Therapeutics: 17 (2)
February 2018
Volume 17, Issue 2
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

Issue Highlights

  • Molecular Basis for Necitumumab Inhibition of EGFR Variants Associated with Acquired Cetuximab Resistance
  • A Novel YAP1 Inhibitor Targets CSC-Enriched Radiation-Resistant Cells and Exerts Strong Antitumor Activity in Esophageal Adenocarcinoma
  • Antitumor Activity of Entrectinib, a Pan-TRK, ROS1, and ALK Inhibitor, in ETV6-NTRK3–Positive Acute Myeloid Leukemia
  • Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer

Jump to

  • Highlights
  • MCT Focus: Developmental Therapeutics in Radiation Oncology
  • Small Molecule Therapeutics
  • Cancer Biology and Translational Studies
  • Large Molecule Therapeutics
  • Models and Technologies
Advertisement
  • Most Cited
  • Most Read
Loading
  • CD137 Agonist mAb with Reduced Liver Toxicity
  • Truncated BRCA2 Contributes to PARPi Resistance
  • ERPAS to Predict Response to Endocrine Therapy
  • CDK8/19 Inhibitors Enhance NK-Cell–Mediated Cancer Therapy
  • Sialoglycan mAb for Cancer Immunotherapy
More...
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement